Quest for the right Drug
הלדול 5 מ"ג HALDOL 5 MG (HALOPERIDOL)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The safety of haloperidol was evaluated in 284 haloperidol-treated patients who participated in 3 placebo-controlled clinical studies and in 1295 haloperidol-treated patients who participated in 16 double-blind active comparator-controlled clinical studies. Based on pooled safety data from these clinical studies, the most commonly reported adverse reactions were: extrapyramidal disorder (34%), insomnia (19%), agitation (15%), hyperkinesia (13%), headache (12%), psychotic disorder (9%), depression (8%), weight increased (8%), tremor (8%), hypertonia (7%), orthostatic hypotension (7%), dystonia (6%) and somnolence (5%). In addition, the safety of haloperidol decanoate was evaluated in 410 patients who participated in 3 comparator studies (1 comparing haloperidol decanoate versus fluphenazine and 2 comparing the decanoate formulation to oral haloperidol), 9 open label studies and 1 dose response study. Table 4 lists adverse reactions as follows: • Reported in clinical studies with haloperidol. • Reported in clinical studies with haloperidol decanoate and relate to the active moiety. • From postmarketing experience with haloperidol and haloperidol decanoate. Adverse reaction frequencies are based on (or estimated from) clinical trials or epidemiology studies with haloperidol, and classified using the following convention: Very common: ≥1/10 Common: ≥1/100 to <1/10 Uncommon: ≥1/1,000 to <1/100 Rare: ≥1/10,000 to <1/1,000 Very rare: <1/10,000 Not known: cannot be estimated from the available data. The adverse reactions are presented by System Organ Class and in order of decreasing seriousness within each frequency category. Table 4: Adverse reactions System Adverse Reaction Organ Class Frequency Very Common Uncommon Rare Not known Common Blood and Leukopenia Pancytopenia lymphatic Agranulocytosis system Thrombocytopeni disorders a Neutropenia Immune Hypersensitivit Anaphylactic system y reaction disorders Endocrine Hyperprolactinaem Inappropriate disorders ia antidiuretic hormone secretion Metabolic Hypoglycaemia and nutritional disorders Psychiatric Agitation Psychotic Confusional disorders Insomnia disorder state Depression Loss of libido Libido decreased Restlessness Nervous Extrapyramid Tardive Convulsion Neuroleptic Akinesia system al disorder dyskinesia Parkinsonism malignant Cogwheel disorders Hyperkinesia Akathisia Sedation syndrome rigidity Headache Bradykinesia Muscle Motor dysfunction Masked facies Dyskinesia contractions Nystagmus Dystonia involuntary Hypokinesia Hypertonia Dizziness Somnolence Tremor Eye disorders Oculogyric Vision blurred crisis Visual disturbance Cardiac Tachycardia Ventricular disorders fibrillation Torsade de pointes Ventricular tachycardia Extrasystoles Vascular Hypotension disorders Orthostatic hypotension System Adverse Reaction Organ Class Frequency Very Common Uncommon Rare Not known Common Respiratory, Dyspnoea Bronchospasm Laryngeal thoracic and oedema mediastinal Laryngospasm disorders Gastrointestin Vomiting al disorders Nausea Constipation Dry mouth Salivary hypersecretio n Hepatobiliary Liver Hepatitis Acute hepatic disorders function test Jaundice failure abnormal Cholestasis Skin and Rash Photosensitivit Angioedema subcutaneous y reaction Dermatitis tissue Urticaria exfoliative disorders Pruritus Leukocytoclastic Hyperhidrosis vasculitis Musculoskelet Torticollis Trismus Rhabdomyolysis al and Muscle rigidity Muscle twitching connective Muscle spasms tissue Musculoskelet disorders al stiffness Renal and Urinary urinary retention disorders Pregnancy, Drug withdrawal puerperium syndrome and perinatal neonatal (see conditions section 4.6) Reproductive Erectile Amenorrhoea Menorrhagia Priapism system and dysfunction Galactorrhoea Menstrual Gynaecomastia breast Dysmenorrhoe disorder disorders a Sexual Breast pain dysfunction Breast discomfort General Hyperthermia Sudden death disorders and Oedema Face oedema administratio Gait Hypothermia n site disturbance conditions Investigations Weight Electrocardiogram increased QT prolonged Weight decreased Electrocardiogram QT prolonged, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), torsade de pointes and sudden death have been reported with haloperidol. Class effects of antipsychotics Cardiac arrest has been reported with antipsychotics. Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotics. The frequency is unknown. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse reactions should be reported to the Ministry of Health according to the National Regulation by using an online form at the following link: https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Psychotic disorders, Gilles de la Tourette's syndrome, Huntington's chorea
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף